Showing results (141-150 of 178) with videos related to

Sort By:
Pageof 18
Annals of the Rheumatic Diseases|December 21, 2022
Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trialRenske Cf Hebing, Marry Lin, Maja Bulatovic Calasan, et al.
Clinical Rheumatology|May 10, 2022
Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational studyRieke Alten, Xavier Mariette, René-Marc Flipo, et al.
The Journal of Rheumatology|October 3, 2012
Different type of carotid arterial wall remodeling in rheumatoid arthritis compared with healthy subjects: a case-control studyAlper M Van Sijl, Katja Van Den Hurk, Mike J L Peters, et al.
BMC Musculoskeletal Disorders|January 14, 2014
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION studyHubert G Nüßlein, Rieke Alten, Mauro Galeazzi, et al.
Rheumatology (Oxford, England)|June 2, 2016
The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritisNicole P C Konijn, Lilian H D van Tuyl, Maarten Boers, et al.
Science Translational Medicine|February 1, 2019
Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assayLea C Berkhout, Merel J l'Ami, Jill Ruwaard, et al.
British Journal of Clinical Pharmacology|November 3, 2022
A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitisMaartje M van de Meeberg, Renske C F Hebing, Michael T Nurmohamed, et al.
Expert Opinion on Drug Safety|August 5, 2021
Patients' perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomesLeanne J Kosse, Gerda Weits, Harald E Vonkeman, et al.
Rheumatology (Oxford, England)|June 10, 2022
Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cellsMerel A A Opdam, J H de Leijer, Nathan den Broeder, et al.
Expert Opinion on Drug Safety|August 29, 2022
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort studyLieke H Roest, Leanne J Kosse, Jette A van Lint, et al.
Pageof 18